Fasken Martineau DuMoulin LLP advised LSK Technologies Inc. on the sale to Nicoya, assisted by Osler, Hoskin & Harcourt LLP.
Nicoya Lifesciences, which provides advanced analytical instruments to researchers in the biotech and pharmaceutical industries, has acquired fellow University of Toronto startup LSK Technologies.
The financial terms of the transaction, which will see Nicoya acquire LSK’s team, tech, and customers, were not disclosed.
LSK Technologies Inc. (LSK) is a startup founded by U of T alumni Seray Çiçek and Yuxiu (Livia) Guo with professor Keith Pardee. The trio invented their portable diagnostic devices to help strained health-care systems in remote Latin American communities meet the threat of the Zika virus.
When the coronavirus pandemic hit in 2020, they quickly expanded their platform to diagnose COVID-19 in areas without adequate lab facilities.
LSK’s technology enables nucleic acid and protein testing of versatile samples at any time, generating results in 30 minutes while providing real time access to laboratory-grade results.
Nicoya Lifesciences is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors.
The Fasken team consisted of Will Shaw (Picture), Ryan Schnier and Laura Fetter.
The Osler team consisted of Chad Bayne, Chres Lee, Jennifer Humphrey (Emerging and High Growth Companies), Nathaniel Lipkus, Ryan Howes (Intellectual Property) and Darren Gill (Articling Student).
Involved fees earner: Laura Fetter – Fasken Martineau; Ryan Schnier – Fasken Martineau; Will Shaw – Fasken Martineau; Chad Bayne – Osler Hoskin & Harcourt; Ryan Howes – Osler Hoskin & Harcourt; Jennifer Humphrey – Osler Hoskin & Harcourt; Chres Lee – Osler Hoskin & Harcourt; Nathaniel Lipkus – Osler Hoskin & Harcourt;